生物药物和小分子治疗牛皮:当前和未来的进展
Luca Potestio1, Nello Tommasino1, Michela D'Agostino1
1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy.
Drugs in context
|November 28, 2025
概括
新的全身疗法,包括生物药物和小分子,正在彻底改变牛皮治疗. 药物遗传学和人工智能的未来进步有望为牛皮患者提供更个性化和更有效的治疗.
科学领域:
- 皮肤病学和免疫学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 了解牛皮病理生理学已经推动了新的生物和小分子疗法.
- 目前的治疗方法已经彻底改变了中度至重度的牛皮管理,但挑战仍然存在.
研究的目的:
- 探索牛皮的新系统疗法,包括已批准和新兴的生物药物和小分子.
- 突出 psoriasis 治疗的未来方向,解决未满足的需求.
主要方法:
- 现有医学文献的叙述性审查.
- 搜索的数据库包括PubMed,Ovid,Scopus,Embase和Cochrane图书馆,截至2025年6月30日.
主要成果:
- 生物制剂和小分子代表了牛皮治疗的重大进步.
- 仍然存在未满足的需求,包括特定的表型,并发症,耐药性和成本.
结论:
- 持续的监视和现实世界的证据对于新手的特工至关重要.
- 药物遗传学和人工智能有可能在牛皮管理中彻底改变精准医学.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
219
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
219
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Microorganisms in Medicine and Therapeutics
917
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
917
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
EPS and iPS Cells in Disease Research
3.3K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.3K


